FDA draft guidances seek to maintain accurate drug information in new media.
Changes are needed to maintain US biopharma innovation leadership.
More media options open publishing opportunities for bioprocessing experts and authors.
ISPE and PDA take on the challenge of recommending quality metrics.
Single-use systems and other technologies drive process efficiencies, but there is room for improvement.
Generics, market dynamics, and global demand are changing drug spending patterns.
Higher wages and employment rates give biopharm professionals an edge over counterparts in other industries.
The employment picture brightened a bit, but biopharma employees still seek better compensation.
The JOBS Act and FDASIA show early signs of accelerating drug development.